

## Global Health 2035: WDR 1993 @20 Years

### **The World Bank's World Development Report 1993**

- Evidence-based health expenditures are an investment not only in health, but in economic prosperity
- Additional resources should be spent on cost-effective interventions to address high-burden diseases







### **The Lancet Commission on Investing in Health**


- Re-examines the case for investing in health
- Proposes a health investment framework for low- and middle-income countries
- Provides a roadmap to achieving gains in global health through a 'grand convergence'

## **Global health 2035: a world converging within a generation**

Dean T Jamison\*, Lawrence H Summers\*, George Alleyne, Kenneth J Arrow, Seth Berkley, Agnes Binagwaho, Flavia Bustreo, David Evans, Richard G A Feachem, Julio Frenk, Gargee Ghosh, Sue J Goldie, Yan Guo, Sanjeev Gupta, Richard Horton, Margaret E Kruk, Adel Mahmoud, Linah K Mohohlo, Mthuli Ncube, Ariel Pablos-Mendez, K Srinath Reddy, Helen Saxenian, Agnes Soucat, Karen H Ulltveit-Moe, Gavin Yamey








## Full Income: A Better Way to Measure the Returns from Investing in Health



Between 2000 and 2011, about a quarter of the growth in full income in low-income and middle-income countries resulted from VLYs gained

THE LANCET GLOBAL HEALTH 2015

## With Full Income Approach, Convergence Has Impressive Benefit: Cost Ratio



THE LANCET GLOBAL HEALTH 2015

## Sources of Financing for Convergence

Economic growth	Mobilization of domestic resources	Inter-sectoral reallocations and efficiency gains	Development assistance for health
<ul style="list-style-type: none"> <li>IMF estimates \$9.6 trillion/y from 2015-2035 in low- and lower middle-income countries</li> <li><b>Cost of convergence (\$70 billion/y) is less than 1% of anticipated growth</b></li> </ul>	<ul style="list-style-type: none"> <li>Taxation of tobacco, alcohol, sugar “win-wins”</li> <li>Broadening and strengthening tax base</li> </ul>	<ul style="list-style-type: none"> <li>Removal of fossil fuel subsidies, health sector efficiency</li> <li>Subsidies account for an 3.5% of GDP on a post-tax basis</li> </ul>	<ul style="list-style-type: none"> <li>Will still be crucial for achieving convergence</li> </ul>

THE LANCET GLOBAL HEALTH 2035

## Global Health 2035: 4 Key Messages

A **grand convergence** in health is achievable within our lifetime

The **returns from investing in health** are extremely impressive

**Fiscal policies** are a powerful, underused lever for curbing non-communicable diseases and injuries

Progressive pathways to **universal health coverage** are an efficient way to achieve health and financial protection

THE LANCET GLOBAL HEALTH 2035

## Single Greatest Opportunity To Curb NCDs is Tobacco Taxation

### 50% rise in tobacco price from tax increases in China

- prevents 20 million deaths + generates extra \$20 billion/y in next 50 y
- additional tax revenue would fall over time **but** would be higher than current levels even after 50 y
- largest share of life-years gained is in bottom income quintile



THE LANCET GLOBAL HEALTH 2015

## We Also Argue for Taxes on Sugar e.g. product taxes on Sugar-Sweetened Sodas

- Taxing empty calories, e.g. sugary sodas, can reduce prevalence of obesity and raise public revenue
- These taxes do not hurt the poor: main dietary problem in low-income groups is *poor dietary quality* and not energy insufficiency



THE LANCET GLOBAL HEALTH 2015

## Lessons from Taxing Tobacco and Alcohol



- Taxes must be **large** to change consumption
- Must prevent **tax avoidance** (loopholes) and **tax evasion** (smuggling, bootlegging)
- Design taxes to **avoid substitution**
- **Young/low-income groups** respond most

THE LANCET GLOBAL HEALTH 2016

## Global Health 2035: 4 Key Messages

A **grand convergence** in health is achievable within our lifetime


The **returns from investing in health** are extremely impressive

**Fiscal policies** are a powerful, underused lever for curbing non-communicable diseases and injuries

Progressive pathways to **universal health coverage** are an efficient way to achieve health and financial protection

THE LANCET GLOBAL HEALTH 2016

## Our Recommendation on UHC: Progressive Universalism (Blue Shading)



THE LANCET GLOBAL HEALTH 2015

## Progressive Universalism

Insurance covers whole population

Targets poor by insuring highly cost-effective health interventions for diseases disproportionately affecting poor

Interventions are funded through tax revenues, payroll taxes, or combination

No OOP expenses for defined benefit package of publicly financed services

As resource envelope grows, so does package (as seen in Mexico), e.g. add wider range of interventions for NCDs

THE LANCET GLOBAL HEALTH 2015

## Advantages of Progressive Universalism



- Government does not have to incur costly administrative expenses identifying who is poor (*everyone is covered*)
- Universal package promotes broader support among population and health providers than schemes targeting poor alone—such support helps to sustain financing over time

THE LANCET GLOBAL HEALTH 2016

## A Variant of Progressive Universalism

- *Larger package to whole population with patient copayment but poor are exempted from copay (e.g. Rwanda)*
- Uses a wider variety of financing mechanisms (general taxation, payroll tax, mandatory insurance premiums, copayments)



**Advantages:** wider package, engages non-poor in prepaid mandatory scheme from day 1, transition may be more feasible



**Major disadvantage:** costly to identify poor, to organize and collect copays/premiums

THE LANCET GLOBAL HEALTH 2016

Thank you

**GlobalHealth2035.org**

THE LANCET GLOBAL HEALTH 2035

### Caveats & Challenges

Inherent uncertainties in any modeling exercise

Assumes aggressive coverage levels (typically 90-95% by 2035)—would all countries have the institutional capacity?

Model does not account for role of other development sectors (e.g. climate, water ) or social determinants of health

May over-play or under-play role of R&D

THE LANCET GLOBAL HEALTH 2035